ストックスクリーナーアプリを入手
16.11
0.56%
0.09
アフターアワーズ：
16.11
前日終値:
$16.02
開ける：
$15.73
24時間の取引高:
185.75K
Relative Volume:
0.73
時価総額：
$2.06B
収益：
$7.50M
当期純損益:
$-81.89M
株価収益率:
0.3039
EPS:
53.0176
ネットキャッシュフロー:
$-63.58M
1週間 パフォーマンス:
-1.23%
1か月 パフォーマンス:
+16.49%
6か月 パフォーマンス:
+29.09%
1年 パフォーマンス:
+97.18%
1日の値動き範囲:
$15.60
$16.15
1週間の範囲:
$15.60
$16.53
52週間の値動き範囲:
$7.09
$22.00
Mesoblast Ltd Adr Stock (MESO) Company Profile
MESO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MESO
Mesoblast Ltd Adr
|
16.11 | 2.05B | 7.50M | -81.89M | -63.58M | 53.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Mesoblast Ltd Adr Stock (MESO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-18 | ダウングレード | Jefferies | Buy → Hold |
| 2024-12-23 | ダウングレード | Jefferies | Buy → Hold |
| 2024-09-24 | アップグレード | Maxim Group | Hold → Buy |
| 2024-08-29 | アップグレード | Jefferies | Hold → Buy |
| 2024-07-23 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-08-31 | アップグレード | Jefferies | Hold → Buy |
| 2023-08-07 | ダウングレード | Maxim Group | Buy → Hold |
| 2023-08-04 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-08-04 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-03-09 | 開始されました | William Blair | Outperform |
| 2022-12-06 | ダウングレード | Jefferies | Buy → Hold |
| 2022-09-06 | 開始されました | Piper Sandler | Overweight |
| 2021-04-07 | アップグレード | Maxim Group | Hold → Buy |
| 2020-12-22 | ダウングレード | Maxim Group | Buy → Hold |
| 2020-12-04 | ダウングレード | Chardan Capital Markets | Neutral → Sell |
| 2020-10-22 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2020-08-14 | 繰り返されました | Maxim Group | Buy |
| 2020-05-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-01-31 | 再開されました | H.C. Wainwright | Buy |
| 2018-03-22 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2018-02-28 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2017-08-31 | 開始されました | Oppenheimer | Outperform |
| 2017-06-08 | 開始されました | Cantor Fitzgerald | Buy |
すべてを表示
Mesoblast Ltd Adr (MESO) 最新ニュース
Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs - GlobeNewswire Inc.
Mesoblast Limited $MESO Shares Acquired by Cubist Systematic Strategies LLC - Defense World
Mesoblast Secures Option for US$50 Million Convertible Note Issuance - Sharecafe
Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes - ADVFN Brasil
Mesoblast secures up to US$50m in fresh funding through convertible note agreements - Biotech Dispatch
Canaccord Genuity initiates Mesoblast stock with Buy rating on cell therapy potential - Investing.com
Company’s Banking Stock: Dissecting a -4.28% Quarterly Revenue Decline Amid Growth - investchronicle.com
Novagold Resources Inc (NG) Stock: A Year of Decreases and Increases - investchronicle.com
TV’s 2025 Market Dance: Down -20.11% – Time to Invest? - investchronicle.com
Mesoblast Ltd ADR Inc. (MESO) Price Performance: A Comparative Analysis with Competitors - investchronicle.com
Cango Inc ADR (CANG) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - investchronicle.com
Innodata Inc (INOD) Stock: A Year of Market Movement, Down and Up - investchronicle.com
BILL Holdings Inc Inc. (BILL) Price Performance: A Fundamental Analysis Perspective - investchronicle.com
Burford Capital Limited: Navigating Market Fluctuations with a 3.10B Market Cap - investchronicle.com
Chagee Holdings Ltd. ADR (CHA) Stock: A Year of Highs and Lows - investchronicle.com
Nano X Imaging Ltd (NNOX) Stock: The Story of a 52-Week Stock Range - investchronicle.com
WGRX Stock Update: Wellgistics Health Inc’s Banking’s Market Struggles and Potential Opportunities - investchronicle.com
ZTO’s Stock Market Adventure: -5.37% YTD Growth Amidst Volatility - investchronicle.com
MGRX’s Market Whiplash: -74.88% YTD Decline, -16.49% Plunge in 30 Days - investchronicle.com
Mesoblast stock soars after reporting first Ryoncil sales - Investing.com India
Sonim Technologies Inc (SONM) Stock: Uncovering 52-Week Market Trends - investchronicle.com
An In-Depth Look at Trident Digital Tech Holdings Ltd. ADR Inc. (TDTH) Price Performance During Market Crashes - investchronicle.com
BTCM: Riding the Market Waves of Growth and Decline in 2025 - investchronicle.com
Perspective Therapeutics Inc (CATX Stock: A Sea of Opportunity - investchronicle.com
DallasNews Corporation (DALN) Stock: Uncovering 52-Week Market Trends - investchronicle.com
DraftKings Inc (DKNG) Stock: Uncovering a 52-Week Range and Trading Volume - investchronicle.com
TSM’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Krispy Kreme Inc (DNUT) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket - Benzinga
All Markets & Instruments Available to Trade - Capital.com
ASX Lunch Wrap: ASX and gold reset record highs; but Origin cuts its LNG forecast - Stockhead
Why are Mesoblast shares in a trading halt? - The Motley Fool Australia
Mesoblast Limited Initiates Trading Halt Pending Financing Announcement - TipRanks
ASX December health sector winners… and a 91pc drop for a trial-flopped stock - Stockhead
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
Mesoblast Stock Soars to 52-Week High, Hits $19.15 - Investing.com
Mesoblast stock soars to 52-week high, hits $12.21 - Investing.com
Mesoblast Stock Soars to 52-Week High, Hits $12.19 - Investing.com
Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential (NASDAQ:MESO) - Seeking Alpha
Mesoblast: Rolling The Dice On Cellular Medicines (NASDAQ:MESO) - Seeking Alpha
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners - Stockhead
Mesoblast Limited: Back From The Dead (NASDAQ:MESO) - Seeking Alpha
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - TradingView
11 Best ASX Stocks To Buy Now - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
10 Best Australian Stocks To Buy - Yahoo Finance
Philip R. Krause, M.D., Former FDA Deputy Chief For Vaccines, Joins Mesoblast Board - Barchart.com
Maxim Group Stick to Their Buy Rating for Mesoblast Ltd - Investing.com
Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy - Novartis
ASX dives as Trump tests COVID positive - The Australian
The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal - Yahoo Finance
Mesoblast Ltd Adr (MESO) 財務データ
収益
当期純利益
現金流量
EPS
2.36%
1.10%
大文字化:
|
ボリューム (24 時間):